
-
Stocks diverge as bitcoin hits record high
-
Spain suffers third wildfire death, Greece beats back flames
-
Liverpool 'agree deal' for Parma prospect Leoni
-
Foreign NGOs say new Israeli rules keep them from delivering Gaza aid
-
Japan's grand tea master Sen Genshitsu dies at 102: reports
-
Water shortages plague Beirut as low rainfall compounds woes
-
Germany's Thyssenkrupp cuts targets as US tariffs weigh
-
UK PM hosts Zelensky in London on eve of US-Russia summit
-
Brady didn't understand football, says Rooney after 'work ethic' jibe
-
Greek firefighters make progress against wildfires
-
UK economy slows less than feared after tariffs
-
Markets mixed as bitcoin hits new high
-
PSG begin French title defence as Pogba returns home and Paris FC step up
-
At least 40 dead in Sudan's worst cholera outbreak in years: MSF
-
Zelensky in London to meet PM ahead of US-Russia summit
-
French dictionary gets bad rap over Congolese banana leaf dish
-
Alaska: a source of Russian imperial nostalgia
-
Last chance saloon for global plastic pollution treaty
-
India to bid for Commonwealth Games as part of Olympic push
-
North Korea denies removing border loudspeakers
-
Despite risks, residents fight to protect Russian national park
-
Asian markets mixed as bitcoin surges to new high
-
War-weary Ukrainians find solace by frontline lake
-
Okinawa a reluctant host for US troops 80 years after WWII
-
Alonso's Real Madrid start La Liga with fresh energy
-
Liverpool splash out to secure status as Premier League's top dogs
-
Hong Kong court postpones closing arguments in Jimmy Lai trial
-
Top Japanese fighter retires to support comatose boxer brother
-
Boars, Butterflies or Bees? Public to name Papua New Guinea's NRL team
-
Defending champions Sinner, Sabalenka reach Cincinnati quarters
-
Bolivia presidential hopefuls make last push for votes
-
Trump orders space regulations eased in win for Musk
-
Trump warns of make-or-break chance with Putin as pressure mounts
-
From Snoop Dogg to Tom Brady, stars flock to English second-tier clubs
-
Inside Trump's 'Alligator Alcatraz': detainees allege abuse in a legal black hole
-
Scientists find surprising sex reversal in Australian birds
-
Taylor Swift sets October release for new album
-
Sinner, Sabalenka sail into Cincinnati quarter-finals
-
Oh carp: UK's Lammy on the hook after fishing with Vance without licence
-
ANITA & ZAHA Introduces Exclusive "Made in France" Natural Cosmetics
-
Sinner shrugs off rain to dispatch Mannarino in Cincinnati
-
Tainted fentanyl blamed for 87 hospital deaths in Argentina
-
Eyeing robotaxis, Tesla hiring New York test car operator
-
NBA approves $6.1bn sale of Boston Celtics
-
PSG beat Tottenham on penalties to win UEFA Super Cup after late comeback
-
Cowboys owner Jones says experimental drug saved him after cancer diagnosis
-
Striking Boeing defense workers turn to US Congress
-
PSG beat Tottenham on penalties to win UEFA Super Cup
-
Hong Kong court to hear closing arguments in mogul Jimmy Lai's trial
-
US singer Billy Joel to sell off motorcycles due to health condition

US govt sends drugmakers initial offers in price talks
The US government said it was making initial offers to drugmakers Thursday as part of Medicare negotiations meant to lower the prices many older Americans would pay for 10 medicines.
The move comes as President Joe Biden pushes to rein in health care costs ahead of November's election.
The negotiation program came on the back of Biden's landmark Inflation Reduction Act, a major package of energy transition policy and social reforms.
This allowed Medicare, the federal health insurance for seniors, to start negotiating drug costs -- a first in its nearly 60-year existence.
"This is the first time ever that Medicare is not accepting the drug prices the pharmaceutical companies set," the White House said in a statement on Thursday.
It did not reveal how much it offered for each drug.
A Johnson & Johnson spokesperson told AFP the company has received an initial price from the government but said it was "respecting the confidential nature of the process."
Last October, major drugmakers behind 10 selected medicines for serious illnesses grudgingly agreed to negotiate on cutting prices.
But pharmaceutical companies have pushed back against the initiative, earlier saying that they came on board as they had no choice.
While the US government is initially limited to picking 10 drugs for price talks, it can expand the program in subsequent years.
The drugs include Farxiga by AstraZeneca used against diabetes, Entresto by Novartis to treat heart failure, as well as anticoagulant Eliquis -- used by millions of Medicare beneficiaries.
According to the White House, nine million seniors on Medicare were prescribed the 10 drugs in 2022, spending some $3.4 billion out-of-pocket that year.
The statement also took aim at Big Pharma, which the White House said "charged Americans two to three times more" than in other countries, even when accounting for rebates and discounts.
Biden, who is campaigning for reelection with a large focus on easing voters' financial burdens, said in a separate statement: "My Administration won't stop fighting to lower health care costs for seniors and families."
New negotiated prices for the 10 prescription drugs are set to be announced later this year.
Medicare is expected to negotiate prices for up to 60 drugs over the next four years, and up to an additional 20 drugs each year after that.
Several companies have taken legal action challenging the provisions.
A.AbuSaada--SF-PST